Accuray INC (ARAY) — SEC Filings

Overview

Accuray INC (ARAY) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 31, 2025: Accuray Incorporated filed an 8-K on December 30, 2025, reporting events as of December 27, 2025. The filing pertains to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. It also include

Sentiment Summary

Across 38 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 33 neutral, 2 mixed. The dominant filing sentiment for Accuray INC is neutral.

Filing Type Overview

Accuray INC (ARAY) has filed 1 3, 21 8-K, 6 10-Q, 1 DEFA14A, 2 DEF 14A, 2 10-K, 3 SC 13G/A, 2 SC 13G with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (38)

• 3 Filing — 3 · Apr 17, 2026
• 8-K Filing — 8-K · Apr 6, 2026
• Accuray Inc. Files 8-K: Officer/Director Changes & Financials — 8-K · Dec 31, 2025 Risk: medium
  Accuray Incorporated filed an 8-K on December 30, 2025, reporting events as of December 27, 2025. The filing pertains to the departure of directors or certain o
• Accuray Inc. Files 8-K: Material Agreement, Exit Costs, Equity Sales — 8-K · Dec 16, 2025 Risk: medium
  On December 12, 2025, Accuray Incorporated entered into a Material Definitive Agreement. The company also reported costs associated with exit or disposal activi
• Accuray Inc. Files 8-K on Officer Changes and Shareholder Votes — 8-K · Nov 19, 2025 Risk: medium
  Accuray Incorporated filed an 8-K on November 19, 2025, reporting events as of November 13, 2025. The filing covers the departure of directors or certain office
• Accuray's Q1 Loss Widens to $21.7M Amid Revenue Dip, Soaring Interest Costs — 10-Q · Nov 5, 2025 Risk: high
  Accuray Inc. (ARAY) reported a significant net loss of $21.678 million for the three months ended September 30, 2025, a substantial increase from the $3.954 mil
• Accuray Inc. Files DEFA14A Proxy Materials — DEFA14A · Oct 20, 2025 Risk: low
  Accuray Incorporated filed a Definitive Additional Materials (DEFA14A) on October 20, 2025, related to its proxy statement. The filing indicates no fee was requ
• Accuray Sets Nov. 13 Virtual Shareholder Meeting for Key Votes — DEF 14A · Oct 1, 2025 Risk: medium
  Accuray Inc. (ARAY) is holding its 2025 Annual Meeting of Stockholders on November 13, 2025, to address several key proposals. Stockholders will vote on the ele
• Accuray Inc. Files 8-K on Executive Changes and Financials — 8-K · Sep 19, 2025 Risk: low
  Accuray Incorporated filed an 8-K on September 19, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointment
• Accuray Pushes AI-Driven Radiation Therapy Amid Global Expansion — 10-K · Aug 28, 2025 Risk: medium
  Accuray Inc. (ARAY) filed its 10-K for the fiscal year ended June 30, 2025, highlighting its focus on advanced radiation therapy systems like the CyberKnife and
• Accuray Inc. Announces Executive and Director Changes — 8-K · Aug 22, 2025 Risk: low
  Accuray Incorporated announced on August 19, 2025, changes in its executive and director roles. The company elected new directors and appointed new officers, al
• Accuray to be Acquired by Health Catalyst Capital for $1.1B — 8-K · Aug 13, 2025 Risk: medium
  Accuray Incorporated announced on August 13, 2025, that it has entered into a definitive agreement to be acquired by a subsidiary of Health Catalyst Capital Man
• Accuray Inc. Files 8-K: Agreements, Financing, and Executive Changes — 8-K · Jun 6, 2025 Risk: medium
  On June 3, 2025, Accuray Incorporated entered into a material definitive agreement, likely related to financing or a significant operational change, as indicate
• Accuray Inc. Files Q3 2025 10-Q with Financial Details — 10-Q · May 2, 2025 Risk: medium
  Accuray Inc. reported its Q3 2025 results for the period ending March 31, 2025. The company's financial statements include details on its common stock, selling
• Accuray Inc. Files 8-K on Financials — 8-K · Apr 30, 2025 Risk: low
  Accuray Incorporated filed an 8-K on April 30, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD disc
• Accuray CFO Departs; Interim CFO Appointed — 8-K · Feb 7, 2025 Risk: medium
  Accuray Incorporated announced on February 3, 2025, the departure of its Chief Financial Officer, Michael J. Anstey. The company has appointed Suzanne T. Foster
• Accuray Inc. Files 10-Q for Q2 2025 — 10-Q · Feb 5, 2025 Risk: medium
  Accuray Inc. reported its second quarter results for the period ending December 31, 2024. The company's filing covers financial data and business operations for
• Accuray Inc. Files 8-K for Jan 21, 2025 — 8-K · Jan 21, 2025 Risk: low
  Accuray Incorporated filed an 8-K on January 21, 2025, to report on Regulation FD disclosures and financial statements. The filing does not contain specific fin
• Accuray to be Acquired by Elekta for $1 Billion — 8-K · Dec 11, 2024 Risk: medium
  Accuray Incorporated announced on December 6, 2024, that it has entered into a definitive agreement to be acquired by Elekta AB for approximately $1.0 billion.
• Accuray Inc. Files 8-K: Director/Officer Changes & Shareholder Votes — 8-K · Nov 25, 2024 Risk: medium
  Accuray Incorporated filed an 8-K on November 25, 2024, reporting events as of November 21, 2024. The filing indicates changes related to the departure or elect
• Accuray Inc. Files Q2 2024 10-Q — 10-Q · Nov 6, 2024 Risk: medium
  Accuray Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for the quarter. Specific
• Accuray Inc. Files 8-K Report — 8-K · Oct 21, 2024 Risk: low
  On October 21, 2024, Accuray Incorporated filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits. No spe
• Accuray Inc. Reports Director/Officer Changes & Compensation Updates — 8-K · Oct 15, 2024 Risk: medium
  Accuray Incorporated filed an 8-K on October 15, 2024, reporting changes in its board of directors and executive officers, along with updates to compensatory ar
• Accuray Inc. Files Definitive Proxy Statement — DEF 14A · Oct 4, 2024 Risk: low
  Accuray Incorporated filed a Definitive Proxy Statement (DEF 14A) on October 4, 2024, for the fiscal year ending June 30, 2024. The filing pertains to the compa
• Accuray Inc. Files 2024 Annual Report — 10-K · Sep 19, 2024 Risk: medium
  Accuray Inc. filed its 10-K for the fiscal year ending June 30, 2024, reporting on its operations in surgical and medical instruments. The company's fiscal year
• Accuray Inc. Enters Material Definitive Agreement — 8-K · Sep 16, 2024 Risk: medium
  On September 12, 2024, Accuray Incorporated entered into a Material Definitive Agreement. The filing does not provide specific details about the agreement, its
• SC 13G/A Filing — SC 13G/A · Sep 6, 2024
• Accuray Inc. Announces CFO Departure, New Directors — 8-K · Sep 3, 2024 Risk: medium
  On August 28, 2024, Accuray Incorporated filed an 8-K report detailing the departure of its Chief Financial Officer, Suzanne Foster, effective August 27, 2024.
• Accuray Inc. Files 8-K on Financials — 8-K · Aug 14, 2024 Risk: low
  Accuray Incorporated filed an 8-K on August 14, 2024, reporting on its results of operations and financial condition. The filing also includes Regulation FD dis
• Accuray Inc. Elects New Directors, Reports Executive Compensation — 8-K · May 10, 2024 Risk: low
  Accuray Incorporated announced on May 6, 2024, the election of two new directors, Dr. Suzanne L. Brundage and Mr. Kevin L. Johnson, to its Board of Directors. T
• Accuray Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 8, 2024 Risk: low
  ACCURAY INC (ARAY) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. Accuray Inc. filed a 10-Q report for the period ending March 31, 2024. The filin
• Accuray Inc. Files 8-K for Material Agreement and Financials — 8-K · May 1, 2024 Risk: medium
  On April 25, 2024, Accuray Incorporated (ACGY) entered into a Material Definitive Agreement. The company also reported its Results of Operations and Financial C
• SC 13G Filing — SC 13G · Feb 13, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• Neuberger Berman Amends Accuray Stake: 5.5M Shares Disclosed — SC 13G/A · Feb 12, 2024 Risk: medium
  Neuberger Berman Group LLC, a Delaware-based investment firm, filed an amended SC 13G/A on February 12, 2024, disclosing its updated ownership in Accuray Inc. A
• Accuray Inc. Files 10-Q for Period Ending December 31, 2023 — 10-Q · Feb 7, 2024 Risk: medium
  ACCURAY INC (ARAY) filed a Quarterly Report (10-Q) with the SEC on February 7, 2024. Accuray Inc. filed its 10-Q report for the period ending December 31, 2023.
• Accuray Files 8-K on Financial Results & Reg FD Disclosure — 8-K · Jan 31, 2024
  Accuray Incorporated filed an 8-K on January 31, 2024, to report on its results of operations and financial condition, as well as to make a Regulation FD disclo
• BlackRock Discloses 5.0% Passive Stake in Accuray Inc. — SC 13G · Jan 25, 2024
  BlackRock Inc., a major investment firm, reported on January 25, 2024, that as of December 31, 2023, it beneficially owns 5.0% of ACCURAY INC's Common Stock. Th

Risk Profile

Risk Assessment: Of ARAY's 31 recent filings, 1 were flagged as high-risk, 20 as medium-risk, and 10 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Accuray INC's most recent 10-Q filing (Nov 5, 2025):

• Revenue: $93.942 million
• Net Income: -$21.678 million
• EPS: N/A
• Debt-to-Equity: 2.04
• Cash Position: $63.344 million
• Operating Margin: -12.04%
• Total Assets: $456.816 million
• Total Debt: $139.169 million

Key Executives

• Madison, Wisconsin
• China
• United States
• Switzerland
• Japan
• Suzanne Winter
• Michael J. Anstey
• Suzanne T. Foster
• Suzanne Foster
• Christopher J. R. Williams
• Dr. David J. Shulkin
• Ms. Pamela G. Kirby
• Dr. Suzanne L. Brundage
• Mr. Kevin L. Johnson

Industry Context

Accuray Inc. operates in the medical device industry, specifically focusing on radiation oncology systems. The sector is characterized by high R&D costs, long sales cycles, and significant regulatory oversight. Competition comes from established players and emerging technologies, with a growing emphasis on precision medicine and minimally invasive treatments.

Top Tags

corporate-governance (6) · 10-Q (5) · financials (4) · medical-devices (4) · 8-k (4) · officer-changes (3) · Medical Devices (3) · sec-filing (3) · financial-reporting (3) · healthcare (3)

Key Numbers

• Net loss for Q1 2025: $21.678 million — Increased from $3.954 million in Q1 2024, representing a significant deterioration.
• Total net revenue for Q1 2025: $93.942 million — Decreased by 7.5% from $101.545 million in Q1 2024.
• Product revenue for Q1 2025: $37.161 million — Declined by 23.1% from $48.369 million in Q1 2024.
• Service revenue for Q1 2025: $56.781 million — Increased by 6.8% from $53.176 million in Q1 2024.
• Loss from operations for Q1 2025: $11.313 million — Widened from $2.149 million in Q1 2024.
• Interest expense for Q1 2025: $8.052 million — Increased significantly from $2.955 million in Q1 2024.
• Loss from change in fair value of warrant liability for Q1 2025: $1.874 million — A new expense not present in Q1 2024.
• Cash and cash equivalents as of September 30, 2025: $63.344 million — Increased from $57.416 million as of June 30, 2025.
• Accounts receivable, net, as of September 30, 2025: $54.378 million — Decreased from $83.192 million as of June 30, 2025.
• Inventories, net, as of September 30, 2025: $155.503 million — Increased from $141.020 million as of June 30, 2025.
• Filing Date: 2025-10-01 — Date DEF 14A was filed and proxy materials were made available
• Annual Meeting Date: 2025-11-13 — Date of the 2025 Annual Meeting of Stockholders
• Annual Meeting Time: 9:00 a.m. PST — Start time for the virtual Annual Meeting
• Record Date: 2025-09-17 — Date for determining stockholders entitled to vote at the Annual Meeting
• Shares Outstanding: 112,719,901 — Number of common stock shares issued and outstanding on the Record Date

Forward-Looking Statements

• {"claim":"Neuberger Berman will maintain a significant stake in Accuray Inc. for the foreseeable future.","entity":"Neuberger Berman Group LLC","targetDate":"December 31, 2024","confidence":"medium"}

Related Companies

SIEMENS · EKTA B · ACCL · EKTA · ARCY · ACCY · ACGY

Frequently Asked Questions